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Abstract
Prioritizing Primary Prevention Strategies for Cardiovascular Disease at the
Clinic Population Level

Giulio C. Rottaro Castejon, Bradley Richards, and Brita Roy. Section of
General Internal Medicine, Department of Medicine, Yale University School
of Medicine, New Haven, CT
Cardiovascular Disease remains the number one cause of mortality in the United
States with atherosclerotic cardiovascular disease (ASCVD) being a major component.
Lifestyle interventions remain the first line treatment for the prevention of ASCVD, and clinicbased interventions effectively improve rates of healthy lifestyle choices. However, these
programs require additional resources and there is currently no guidance for clinic directors
to understand what lifestyle intervention(s) have the highest value for their unique
population. We propose a novel application of the 10-year ASCVD risk calculator to a clinic
patient cohort, thereby acting as a tool for providers and administrators to develop lifestyle
intervention programs that will have the greatest risk reduction for their clinic population.
We first defined the ASCVD 10-year risk for patient cohorts from four different
primary care clinics in New Haven, CT by normalizing and aggregating individual patient 10year ASCVD risk scores. We then calculated changes to this normalized aggregate risk by
modeling the effects of evidence-based interventions found in Cochrane Reviews of different
efficacy to each of four modifiable risk factors used in the 10-year ASCVD risk calculator.
The four different modifiable risk factors include systolic blood pressure, total cholesterol,
HDL cholesterol and smoking status. A resulting change in each cohort’s normalized
aggregate risk was calculated.
The clinic cohorts had different levels of modeled risk reduction from the same
interventions. The magnitude of reduction was dependent on baseline normalized aggregate
risk and prevalence of risk factor(s) targeted in the interventions. The three clinics where the
baseline normalized aggregate risk was above 100 events per 1,000, patients had a greater
risk reduction from an organizational intervention aimed at improving the quality of treatment
for hypertensive patients compared to all other evidence-based interventions found in
Cochrane Reviews. In the clinic that had a lower baseline normalized aggregate risk, the
highest yield intervention was dietary advice by providers. Our data demonstrate that the
highest yield lifestyle intervention for any clinic may vary depending on the makeup of the
populations and its risk factors.
The tool created in this study can be used by clinic providers and administrators to
estimate the effects of various interventions on the ASCVD risk of their clinic cohort. The
models generated by this tool can be used to guide strategy and prioritize clinic resources
based on the extrapolated effects of evidence based interventions to specific clinic
populations. Furthermore, it may also guide interventions planned to address needs
identified by community health assessments. Because the tool predicts outcomes for
specific patient populations it has the potential to foster the application of evidence-based
practices to population health management.
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Introduction
The 2013 American College of Cardiology and American Heart Association
(ACC/AHA) Guideline on Lifestyle Management to Reduce Cardiovascular Risk
emphasized lifestyle interventions as a crucial component of cardiovascular disease
prevention.1 These guidelines recommend that providers target poor dietary habits,
and physical inactivity given both their prevalence on the general population and
their indirect, yet significant, effect on cardiovascular disease risk.1 Interventions
mentioned in this report include advice to engage in physical activity two to three
times per week, advice to decrease daily sodium intake, advice to follow specific diet
plans available to the public, etc. The effect of such lifestyle interventions varies by
patient, and the intervention with this highest cardiovascular risk reduction is
determined by a patient’s risk factors.2 These interventions are variable in resource
requirements for implementation, but the most effective ones generally require more
resources. As such, it is cost-prohibitive for clinics to make all evidence-based
lifestyle interventions available to their patients.3
Given the high prevalence of modifiable behaviors contributing to
cardiovascular disease risk and the cost of lifestyle interventions there is both a
clinical and financial argument to approach primary cardiovascular disease
prevention at the population level.4 In a 2011 article by Dr. Thomas A. Pearson, he
described the need for both a clinical and population approach to the primary
prevention of cardiovascular disease.4 He went on to say that much of the decline in
cardiovascular mortality over the 20th century was from lifestyle changes in the
American population. Clinics should focus primary prevention efforts on the lifestyle
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interventions with the greatest potential risk reduction.2,5 However, the evidence
available on lifestyle interventions is generalized and may not be applicable across
all clinic populations.4 For example, smoking cessation programs have been
reported to be the most cost-effective intervention for cardiovascular disease
prevention.5 But, in a population with a low prevalence of smoking, these
interventions will be less effective in reducing total risk of cardiovascular disease.
There currently is no method for clinics to quantitatively estimate the expected
effects of published interventions on their population’s cardiovascular risk and
compare interventions against each other.
The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to
Reduce Atherosclerotic Cardiovascular Risk in Adults included a robust risk
calculation model to inform individual level medical decision-making to reduce the
risk of events from atherosclerotic disease.6 This model includes modifiable risk
factors such as lipids levels, blood pressure, and smoking status. In this study, we
explored the use of the ACC/AHA 10-year atherosclerotic cardiovascular disease
(ASCVD) risk calculator as a predictive model to aid in primary disease prevention
strategies at the clinic level. We hypothesized that this model could be modified to
calculate the risk of ASCVD for an entire clinic cohort using data from electronic
health records (EHR). Furthermore, we hypothesized that the effects of lifestyle
interventions on modifiable risk factors can be incorporated in the predictive model
to quantitatively estimate their effect on cohort-wide ASCVD prevention. The tool is
meant to empower individual clinics to estimate the effectiveness of different
evidence-based interventions in the primary prevention of ASCVD.
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Statement of Purpose
The main goal of this study was to create a novel tool that applies the 10-year
ASCVD Risk Calculator to a clinic population to guide primary preventative
strategies for clinic-based patient cohorts. The tool calculated baseline ASCVD risk
for each cohort and estimated the number of prevented ASCVD events for different
interventions. We hypothesized that each cohort would respond differently to the
same interventions, and thus the highest value intervention for a given cohort would
vary depending on the demographics and the rates and distribution of clinical risk
factors. In this study, we first applied the tool to randomly generated cohorts
developing a simulation model as a proof of concept that the magnitude of
cardiovascular event reduction in response to a given lifestyle modification strategy
varies depending on the baseline risk of the population. Then we applied the tool to
four real-world clinic cohorts and extrapolated the effects of several interventions.
Ultimately, this tool may allow primary care clinics to implement the highest yield
intervention for primary ASCVD prevention. This study focused mostly on the theory
and development of such a guidance tool but did not proceed to implementation.

Methods
To study the differential effects of lifestyle modifications on diverse patient
cohorts, we used a three-step analytic approach. First we developed a series of
mathematical models to create a tool to test hypothetical treatment effects using the
10-year ASCVD risk calculator. We then applied the tool to randomly generated
cohorts as a simulation to demonstrate the concept. These randomly generated
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cohorts were designed to appear statistically indistinguishable but to have different
baseline ASCVD risks, thereby being less likely to respond differently to intervention.
Lastly we applied the tool to four real-world clinic cohorts. In this last application we
also extrapolated the effects of non-pharmacologic interventions to determine which
intervention is the best for any given cohort.

Model: Baseline 10-Year ASCVD Risk and Risk Change Equations
We created an algorithm that uses data that can be extracted from EHR
systems to calculate a baseline 10-year ASCVD risk for each patient using the
statistical model from the 2013 ACC/AHA guidelines.6 For an individual, i, the 10year ASCVD risk is represented by ri which is a function of age, gender, race, total
cholesterol (TC), HDL cholesterol (HDL), systolic blood pressure (SBP), diagnosis of
diabetes mellitus (DM), whether or not they are receiving hypertension treatment
(HTN), and whether or not they smoke (S).

𝑟% = 𝑓()*+, 𝑎𝑔𝑒% , 𝑔𝑒𝑛𝑑𝑒𝑟% , 𝑟𝑎𝑐𝑒% , 𝑇𝐶% , 𝐻𝐷𝐿% , 𝑆𝐵𝑃% , 𝐷𝑀% , 𝐻𝑇𝑁% , 𝑆%

Given the limitations of this model the individual risk scores are bounded
between 1% and 30%. We add the calculated individual risk scores for a cohort (C)
to get the expected number of ASCVD events in 10 years (RC), also referred to as
the aggregate risk.
@A

𝑅* =

𝑟%
%BC

This value can be normalized to get the number of predicted ASCVD events
in the next ten years per 1,000 patients, or normalized aggregate risk.
9

Equation 1. Normalized aggregate risk given in number of expected ASCVD
events per 1000 patients in the next 10 years.
𝑅* =

10F
×𝑅*
𝑁*

Using this method to obtain the normalized aggregate risk, we can directly
calculate how changes in the modifiable risk factors will affect the number of
expected ASCVD events in the next 10 years. In other words, we can directly
calculate the number of prevented ASCVD events from an intervention on a clinic
population. Conversely, we can quantify the required changes to a modifiable risk
factor in order to achieve a specific level of reduction in the number of expected
ASCVD events.
Changes in total cholesterol are represented by the average decrease in
total cholesterol (∆𝑇𝐶) applied to all individuals with a 10-year ASCVD risk of 7.5%
or higher per ACC/AHA guidelines. Using these principles, the tool can calculate the
changes to individual risk scores.

∆𝑟% = 0, if 𝑟% < 0.075

∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒% , 𝑔𝑒𝑛𝑑𝑒𝑟% , 𝑟𝑎𝑐𝑒% , 𝑀𝑎𝑥 𝑇𝐶% − ∆𝑇𝐶, 100 , 𝐻𝐷𝐿% , 𝑆𝐵𝑃% , 𝐷𝑀% , 𝐻𝑇𝑁% , 𝑆% − 𝑟% ,
if 𝑟% ≥ 0.075

Note that the final total cholesterol (𝑇𝐶% − ∆𝑇𝐶) is bounded from below by 100
mg/dL to simulate the real-life limitations of cholesterol lowering therapies. Using
these changes to individual risk scores the tool can then set up an equation for
change in normalized aggregate risk, ∆𝑅* .
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Equation 2. General equation for change in normalized aggregate risk of
ASCVD.
10F
∆𝑅* =
𝑁*

@A

∆𝑟%
%BC

These sets of equations provide a direct relationship between changes to the
total cholesterol and the normalized aggregate risk scores. The equations can be
used to directly calculate the number of prevented ASCVD events per 1,000 patients
for the expected population level change in cholesterol from a given intervention
aiming to reduce total cholesterol. For any given cohort ∆𝑅* was calculated for a
range of ∆𝑇𝐶 values from 0 mg/dL to 150 mg/dL by increments of 1 mg/dL.
Changes in HDL Cholesterol are represented by the average increase in
HDL Cholesterol (∆HDL) to all individuals. In this case the change in individual risk
score is given by this equation:

∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒% , 𝑔𝑒𝑛𝑑𝑒𝑟% , 𝑟𝑎𝑐𝑒% , 𝑇𝐶% , 𝐻𝐷𝐿% + ∆𝐻𝐷𝐿, 𝑆𝐵𝑃% , 𝐷𝑀% , 𝐻𝑇𝑁% , 𝑆% − 𝑟%

Similar to total cholesterol, these equations can be used to directly calculate
the number of prevented ASCVD events per 1,000 patients for a given intervention
on HDL cholesterol. For any given cohort ∆𝑅* was calculated for a range of ∆𝐻𝐷𝐿
values from 0 mg/dL to 100 mg/dL by increments of 1 mg/dL.
Changes in systolic blood pressure are represented by the decrease in
systolic blood pressure for all individuals under 60 years of age with a systolic blood
pressure above 140 mmHg and all individuals over 60 years of age with a systolic
blood pressure above 150 mmHg. These rules were adapted from the Eighth Joint
National Committee guidelines.7 Like the total cholesterol model, we have limited the
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final systolic blood pressure (𝑆𝐵𝑃% − ∆𝑆𝐵𝑃) to a lower bound of 110 mmHg for
treated individuals. The individual changes in risk scores are given by:

∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒% , 𝑔𝑒𝑛𝑑𝑒𝑟% , 𝑟𝑎𝑐𝑒% , 𝑇𝐶% , 𝐻𝐷𝐿% , 𝑀𝑎𝑥 𝑆𝐵𝑃% − ∆𝑆𝐵𝑃, 110 , 𝐷𝑀% , 𝑇𝑅𝑈𝐸, 𝑆% − 𝑟% ,
if 𝑆𝐵𝑃% > 140 and 𝑎𝑔𝑒% < 60, or 𝑆𝐵𝑃% > 150 and 𝑎𝑔𝑒% ≥ 60

∆𝑟% = 0, otherwise.

As done previously, these equations can be used to directly calculate the
number of prevented ASCVD events per 1,000 patients for a given intervention on
systolic blood pressure. For any given cohort ∆𝑅* was calculated for range of ∆𝑆𝐵𝑃
values from 0 mmHg to 80 mmHg by increments of 1 mmHg.

Smoking status is a Boolean variable, so interventions are modeled by a
probability of smoking cessation. Using a probability of smoking cessation, we model
the risk score using conditional probability.
We define 𝑟%,)* as the risk for patient i without smoking but leave all other risk
factors unchanged. It is given by:
𝑟%,)* = 𝑓()*+, 𝑎𝑔𝑒% , 𝑔𝑒𝑛𝑑𝑒𝑟% , 𝑟𝑎𝑐𝑒% , 𝑇𝐶% , 𝐻𝐷𝐿% , 𝑀𝑎𝑥 𝑆𝐵𝑃% − ∆𝑆𝐵𝑃, 120 , 𝐷𝑀% , 𝐻𝑇𝑁% , 𝐹𝐴𝐿𝑆𝐸

Using conditional probability, we can calculate a new risk score (𝑟%,^ ) given a
probability (𝑝)* ) that any given patient will quit.
𝑟%,^ = 𝑟%,)* ×𝑝)* + 𝑟% × 1 − 𝑝`a

Which implies:
∆𝑟% = 𝑟%,)* ×𝑝)* − 𝑟% ×𝑝`a = 𝑝)* (𝑟%,)* − 𝑟% )
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Note that if the patient is not a smoker, 𝑟%,)* is equal to 𝑟% and therefore ∆𝑟%
becomes zero. Furthermore, we can use this same principle with the whole cohort
and get the following equation.
∆𝑅a = 𝑝)* (𝑅*,)* − 𝑅* )
∆𝑅a =

10F
𝑝 (𝑅
− 𝑅* )
𝑁* )* *,)*

Note that the last equation reveals a direct linear relationship between ∆𝑅a and
the probability and smoking cessation, 𝑝)* , making this calculation remarkably
simpler than all other. For any given cohort ∆𝑅* was calculated for range of 𝑝)*
values from 0.00 to 1.00 by increments of 0.01.
All the different numerical methods discussed were used to calculate changes
to ∆𝑅* based on changes to a single variable. However, they can also be combined
to calculate ∆𝑅* for any multifactorial intervention such as lifestyle interventions that
may have effects on all modifiable risk factors.

Simulation: Randomly Generated Patient Cohorts for Proof of Concept
For development and proof of concept we first aimed to show how
populations with the same demographics and similar risk factors can have drastically
different baseline aggregate ASCVD risk and sub-sequentially drastically different
responses to risk factor modifications. Therefore, randomly generated patient
cohorts were created using the same probability distribution for all variables across
all patients and cohorts. The randomly generated cohorts were 300 patients in size.
This sample size was chosen because it is large enough to apply the law of large
numbers, yet small enough to still show variability from population to population.
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Furthermore, a patient panel size of 300 patients is within the normal limits for a
single primary care provider. The distribution of the variables is shown in Table 1.
Table 1. Distribution of variables for randomly generated patient cohorts.

Variable Distribution
Age (years) Uniform distribution from 40 to 80
Gender 43% probability of Male, 57% probability of
Race
Total Cholesterol (mg/dL)
HDL Cholesterol (mg/dL)

Female
63% probability of White/Other, 37%
probability of Black
Normal distribution (𝜇 = 182, 𝜎 = 44) with
a lower boundary of 58
Normal distribution (𝜇 = 55, 𝜎 = 19) with a
lower boundary of 6
38% probability of diabetes diagnosis
Normal distribution (𝜇 = 130, 𝜎 = 14) with
a lower boundary of 61

Diabetes Mellitus Diagnosis
Systolic Blood Pressure
(mmHg)
Treatment for hypertension 59% probability of hypertension treatment
Smoking Status 18% probability of smoking

The numbers used to set the mean and standard deviation for total
cholesterol, HDL cholesterol, and systolic blood pressure were based on baseline
numbers from all patients included in analyses of local clinic cohorts described in a
later section (Application: Selection of Local Clinic Cohorts). The percentages of
gender, race, diabetes incidence, smoking incidence and hypertension treatment
incidence were based on the same clinic populations. Given that the 10-Year
ASCVD Risk Calculator can only use two sets of coefficients for race, white/other
and black, no other races were included in the randomly generated patient
populations. The cohorts were randomly generated and therefore may be statistically
different from each other if the means or percentages were compared. To create
cohorts that are statistically indistinguishable, all cohorts with a statistically
significant difference in mean age, total cholesterol, HDL cholesterol or systolic
14

blood pressure or a statistically significant difference in percentage of males, black
patients, diabetes incidence, smoking incidence or hypertension treatment incidence
(using a two-tailed z-test with a p-value of 5%) were discarded and replaced with
new randomly generated cohorts.

Simulation: Variance in Baseline Risk of Randomly Generated Cohorts
We randomly generated ten thousand cohorts that were statistically
indistinguishable from each other. Using Equation 1, the normalized aggregate risk
was calculated for each of these cohorts. The results were displayed in a histogram
(Figure 1) to show the variation in normalized aggregate risk for statistically
indistinguishable populations.

Simulation: Variance in Sensitivity to Interventions of Randomly
Generated Cohorts
We created another 10 randomly generated cohorts using the same
methodology. Once again, these cohorts were statistically indistinguishable based
on two-tailed Z-test with a p-value of 5%. We subjected these ten clinic cohorts to a
range of changes to the modifiable risk factors and the resulting change in
normalized aggregate risk was calculated. The methods by which we calculated the
change in normalized aggregate risk was described in a previous section (To study
the differential effects of lifestyle modifications on diverse patient cohorts, we used a
three-step analytic approach. First we developed a series of mathematical models to
create a tool to test hypothetical treatment effects using the 10-year ASCVD risk
calculator. We then applied the tool to randomly generated cohorts as a simulation
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to demonstrate the concept. These randomly generated cohorts were designed to
appear statistically indistinguishable but to have different baseline ASCVD risks,
thereby being less likely to respond differently to intervention. Lastly we applied the
tool to four real-world clinic cohorts. In this last application we also extrapolated the
effects of non-pharmacologic interventions to determine which intervention is the
best for any given cohort.
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations). The
modifiable risk factors we tested were total cholesterol, HDL cholesterol, systolic
blood pressure and smoking status.

Application: Selection of Local Clinic Cohorts
We intentionally selected four adult primary care clinics in the greater New
Haven, CT area that each serve a unique population with a different demographic
makeup. The first clinic we selected was the primary care internal medicine
residency clinic (SRC), which has a high percentage of Medicaid and African
American patients. The second clinic we selected was the categorical internal
medicine residency program clinic (PCC) which is similar in demographic distribution
to the SRC but larger in size. The third clinic we selected was the student-run
HAVEN Free Clinic (HAVEN), which serves mostly uninsured, undocumented
immigrants from Latin America. The fourth clinic we selected was Yale Internal
Medicine Associates (YIMA), a general internal medicine clinic that serves a larger
percentage of white patients and a lower percentage of Medicaid and uninsured
patients compared to the other clinics selected. All the participating clinics shared
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the same hospital-wide electronic health record (EHR) system (EPIC ™) from which
patient demographic and clinical data was pulled.
For each clinic, patients younger than 40 years of age or older than or equal
to 80 years of age were excluded. Patients who had been reported as deceased on
the EHR were also excluded. Patients who had not visited the clinic to which they
were assigned between January 1st, 2014 and January 1st, 2016 were also excluded
to limit the clinic populations to the patients who are most likely to identify a
physician in that clinic as their primary care provider. Patients with a prior ASCVD
event based on International Classification of Diseases (ICD) 9 and 10 codes were
also excluded from analysis as the ASCVD risk calculator is not designed to predict
their risk. Patients without a systolic blood pressure, total cholesterol, HDL
cholesterol were considered to have incomplete data and excluded from analysis.

Table 2. Description of patient selection process by clinic cohort.
Starting Count
Removed for:
Out of age range
Deceased
Not recently seen
Previous ASCVD
Incomplete Data
Final Patient Count

PCC
9164

SRC
4401

HAVEN
506

YIMA
5859

3619
173
908
680
2653
1131

1261
86
365
494
734
1461

292
0
83
2
88
41

1671
124
642
451
1046
1925

Data on 19,930 patients from the four different clinic sites were extracted from
the shared electronic health record. Of these patients 10,851 had to be removed for
meeting study criteria such as being under the age of 40, over the age of 80,
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deceased, or having a prior history of ASCVD. Of the remaining patients, 4,521 had
missing data such as a valid systolic blood pressure, total cholesterol or HDL
cholesterol. A clinic by clinic breakdown can be found on Table 2.

Application: Independent Variables from Clinic Cohorts
For all patients, the most recent total cholesterol and HDL cholesterol on
record were used for risk calculations. For each patient included, the systolic blood
pressure used in the risk calculation was an average of all systolic blood pressures
found in the EHR for the 2015 calendar year. Blood pressure data collected from an
emergency department were excluded from the analysis, however data from nonprimary care ambulatory visits (e.g., cardiology clinic) or inpatient hospitalizations
were included. A secondary analysis was performed using only the latest recorded
systolic blood pressure.
Treatment for hypertension was based on the list of active outpatient
medications for any given patient. If a patient had at least one antihypertensive
agent in their medication list, they were considered to be receiving hypertension
treatment. The list of medications considered to be antihypertensive agents was
based on the drug classes listed in Table 3.
Table 3. Drug classes considered treatment for hypertension.
ACE Inhibitor
Angiotensin 2 Receptor Blocker
Diltiazem
Renin Inhibitor
Vasodilator

Alpha-1-Antagonist
Beta Blocker
Potassium Sparing Diuretic
Thiazide Diuretic

Alpha-2-Agonist
Calcium Channel Blocker
Loop Diuretic
Thiazide-like Diuretic

Diabetes diagnosis was based on a patient’s diagnosis list, problem list, or
Hemoglobin A1c. Any patient with an ICD 9 or ICD 10 code associated with diabetes
18

mellitus type 1 or type 2 diagnosis was considered to have diabetes mellitus for their
risk calculation. Any patient who ever had a hemoglobin A1c greater than 6.5% was
also considered to have diabetes mellitus for risk calculation.
The EHR has a variable for smoking status associated with every patient
encounter. For the purpose of risk calculation, the smoking status was taken from a
patient’s last encounter. Any patient who identified as a smoker regardless of
quantity or method was labeled as a smoker. For patients who were former smokers
the amount of time since they last smoked was not taken into consideration.
Within all cohorts, there were patients with incomplete information, such as a
lack of blood pressures in the past year or a lack of cholesterol lab data. For these
patients, it was not possible to calculate a baseline 10-year ASCVD risk or to
estimate the effect of any interventions, therefore they were excluded from the final
analysis. The demographic data of patients with missing data was compared against
the data of patient that were included in the final analysis for each individual cohort
using a student’s T-test or a Chi Square Test of Independence with Yate’s
Correction to calculate p-values.

Application: Analysis of Clinic Cohorts
We calculated the baseline normalized aggregate risk for the four clinic
cohorts with Equation 1 using the data from patients who met inclusion criteria and
had complete information. These four clinic cohorts were then subjected to a range
of changes to the four modifiable risk factors. The ranges used and the calculation of
the change in normalized aggregate risk were described in a previous section. (To
study the differential effects of lifestyle modifications on diverse patient cohorts, we
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used a three-step analytic approach. First we developed a series of mathematical
models to create a tool to test hypothetical treatment effects using the 10-year
ASCVD risk calculator. We then applied the tool to randomly generated cohorts as a
simulation to demonstrate the concept. These randomly generated cohorts were
designed to appear statistically indistinguishable but to have different baseline
ASCVD risks, thereby being less likely to respond differently to intervention. Lastly
we applied the tool to four real-world clinic cohorts. In this last application we also
extrapolated the effects of non-pharmacologic interventions to determine which
intervention is the best for any given cohort.
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations) The
modifiable risk factors tested were total cholesterol, HDL cholesterol, systolic blood
pressure and smoking status.

Application: Effect of Quality Improvement Interventions
We conducted a literature search of Cochrane Review Articles for nonpharmacologic interventions that affected any of the four modifiable risk factors in
the 10-year ASCVD risk calculator, systolic blood pressure, total cholesterol, HDL
cholesterol and smoking status. From these reviews, we extracted the effect size on
the modifiable risk factor if it was shown to be statistically significant. For each
intervention, we then applied the effect onto each patient who would have met the
inclusion criteria for the intervention and calculated a new normalized aggregate risk
score.
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Statement of Contributions
The original concept for the development of this tool was theorized by Dr.
Michael Robert O’Brien during his first year as a Robert Wood Johnson Clinical
Scholar. Early prototypes of the tool to calculate baseline 10-year ASCVD risk were
developed by Giulio C. Rottaro and Jinyi Zhu. The literature search, proposal,
development, and data analysis were conducted by Giulio C. Rottaro under the
guidance of Dr. Bradley Richards and Dr. Brita Roy. Raw data was collected directly
from the electronic health records system by the Yale Joint Data Analytics Team.
The protocol was reviewed and approved by the Yale University Human
Investigation Committee (Protocol number 1601017016).

Results
Simulation: Variance in Baseline Risk of Randomly Generated Cohorts
The average normalized aggregate risk for these cohorts was 124.7 events
per 1,000 patients in 10 years. The standard deviation was 4.8 events per 1,000
patients in 10 years. Of the 10,000 cohorts, 464 had a normalized aggregate risk
score that was outside of a 95% confidence interval set by the previously mentioned
mean and standard deviation. The distribution of all 10,000 normalized aggregate
risk scores is displayed on the histogram shown in

Figure 1.
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Figure 1. Histogram of normalized aggregate risk for 10,000 randomly
generated patient cohorts with statistically indistinguishable demographics and risk
factors.
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Simulation: Variance in Sensitivity to Interventions of Randomly
Generated Cohorts

Figure 2. Variances in sensitivity to total cholesterol decreases for randomly
generated cohorts. Each color represents a different randomly generated cohort.
Decreases in normalized aggregate risk of ASCVD events are displayed in expected
ASCVD events per 1,000 patients in the next 10 years.
The mean normalized aggregate risk score for ten randomly generated
cohorts was 123 events per 1,000 patients in 10 years (range: 116-132). Figure 2
shows the decrease in normalized aggregate risk for all ten cohorts resulting from
total cholesterol decreases from 0 to 150 mg/dL applied to patients with a baseline
risk above 7.5%. At 150 mg/dL, the mean decrease in normalized aggregate risk
was 20.5 ASCVD events per 1,000 patients with a standard deviation of 1.7 events.
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Figure 3 shows the decrease in normalized aggregate risk for all ten cohorts
resulting from HDL cholesterol increases from 0 to 100 mg/dL applied to all patients.
At 100 mg/dL, the mean decrease in normalized aggregate risk was 31.4 ASCVD
events per 1,000 patients with a standard deviation of 2.5 events.

Figure 3. Variances in sensitivity to HDL cholesterol increases for randomly
generated cohorts. Each color represents a different randomly generated cohort.
Decreases in normalized aggregate risk of ASCVD events are displayed in expected
ASCVD events per 1,000 patients in the next 10 years.
Figure 4 shows the decrease in normalized aggregate risk for all ten cohorts
resulting from systolic blood pressure decreases from 0 to 80 mmHg applied to
patients who qualified for intervention. The intervention was only applied to patients
who met criteria as described in a previous section. (To study the differential effects
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of lifestyle modifications on diverse patient cohorts, we used a three-step analytic
approach. First we developed a series of mathematical models to create a tool to
test hypothetical treatment effects using the 10-year ASCVD risk calculator. We then
applied the tool to randomly generated cohorts as a simulation to demonstrate the
concept. These randomly generated cohorts were designed to appear statistically
indistinguishable but to have different baseline ASCVD risks, thereby being less
likely to respond differently to intervention. Lastly we applied the tool to four realworld clinic cohorts. In this last application we also extrapolated the effects of nonpharmacologic interventions to determine which intervention is the best for any given
cohort.
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations) At a
decrease of 80 mmHg the average decrease in normalized aggregate risk was 7.2
ASCVD events per 1,000 patients with a standard deviation of 1.1 events.
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Figure 4. Variances in sensitivity to systolic blood pressure decreases for
randomly generated cohorts. Each color represents a different randomly generated
cohort. Decreases in normalized aggregate risk of ASCVD events are displayed in
expected ASCVD events per 1,000 patients in the next 10 years.
Figure 5 shows the decrease in normalized aggregate risk for all ten cohorts
resulting from smoking cessation interventions. The smoking cessation interventions
ranged in probability of cessation from 0.01 to 1.00. With a probability of 1.00 the
average decrease in normalized aggregate risk was 8.7 ASCVD events per 1,000
patients with a standard deviation of 1.4 events.
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Figure 5. Variances in sensitivity to smoking cessation interventions for
randomly generated cohorts. Each color represents a different randomly generated
cohort. Decreases in normalized aggregate risk of ASCVD events are displayed in
expected ASCVD events per 1,000 patients in the next 10 years.

Application: Comparison of Demographic Data for Clinic Cohorts
Across all four clinic cohorts, patients with missing data were on average
younger by about two years (Table 4a and 4b). For three of the clinics cohorts there
were statistically significant differences in race distributions with a higher percentage
of black patients among those included compared to those excluded for missing
data. In three clinic cohorts, the average systolic blood pressure was higher among
those included compared to those excluded for missing data. Across all cohorts
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there was higher prevalence of diabetes mellitus among patients included in the
study compared to those with missing data.
Table 4a and 4b. Table comparing the demographic information for patients
included in the final study versus patients with missing data who were excluded from
the study. Race and ethnicity categories are set by the options available in the EHR.
P-values for continuous variables obtained via student’s T-test. P-values for
categorical variables obtained using Chi Square Test of Independence. P-values
lesser than 0.05 are bolded.
PCC
Included

Missing Data

Number of Patients

1131

2653

Average Age (years)

55.7

53.0

SRC
pvalue
<0.001

Included

Missing Data

1461

734

56.1

53.9

0.277

Gender
41.1%

39.2%

38.5%

39.9%

Female (%)

58.9%

60.8%

61.5%

60.1%

<0.001

0.002

Asian (%)

1.1%

1.5%

0.5%

1.1%

Black (%)

41.8%

36.0%

52.1%

45.4%

Hispanic (%)

1.1%

0.2%

0.6%

0.5%

White (%)
Other/Unknow

0.1%

25.3%

20.9%

28.2%

27.0%

36.1%

25.8%

24.8%

n (%)

0.001

Ethnicity

<0.001
0.541

Male (%)
Race

pValue

0.090

25.1%

30.5%

23.8%

20.4%

74.9%

69.5%

76.2%

79.6%

Current Smokers (%)

14.1%

16.1%

0.143

30.9%

37.1%

0.005

Diabetes Prevalence (%)
Average Systolic Blood
Pressure (mmHg)
Average Total Cholesterol
(mg/dL)
Average HDL Cholesterol
(mg/dL)

43.3%

25.6%

<0.001

42.5%

21.5%

<0.001

129.8

128.0

<0.001

131.8

130.6

0.102

178.0

176.6

0.783

184.2

195.4

0.007

51.2

50.9

0.883

55.9

56.7

0.662

Hispanic (%)
Non-Hispanic
(%)
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HAVEN
Included

Missing Data

Number of Patients

41

88

Average Age (years)

51.5

50.3

YIMA
pValue
0.458

Included

Missing Data

1925

1046

59.0

57.6

0.588

Gender
48.8%

55.7%

41.6%

42.9%

Female (%)

51.2%

44.3%

58.4%

57.1%

0.128

<0.001

Asian (%)

0.0%

0.0%

3.7%

4.2%

Black (%)

2.4%

3.4%

18.8%

10.6%

Hispanic (%)

19.5%

4.5%

0.7%

0.5%

White (%)
Other/Unknown

2.4%

5.7%

66.8%

76.4%

75.6%

86.4%

9.8%

8.2%

(%)

0.957

Ethnicity

<0.001
0.513

Male (%)
Race

pValue

0.009

87.8%

86.4%

10.1%

7.2%

12.2%

13.6%

89.9%

92.8%

Current Smokers (%)

7.3%

15.9%

0.287

9.1%

8.7%

0.772

Diabetes Prevalence (%)
Average Systolic Blood
Pressure (mmHg)
Average Total Cholesterol
(mg/dL)
Average HDL Cholesterol
(mg/dL)

17.1%

12.5%

0.671

22.6%

12.0%

<0.001

125.9

119.4

0.012

128.0

126.8

0.016

193.7

195.0

0.904

190.3

189.5

0.579

52.0

57.6

0.225

60.2

55.9

<0.001

Hispanic (%)
Non-Hispanic
(%)

Application: Modeled Risk Reduction among Actual Clinic Cohorts
The baseline normalized aggregate risk of the SRC cohort was 117.3 ASCVD
events per 1,000 patients in the next 10 years. For the HAVEN cohort it was 55.2
and for the PCC and YIMA cohorts it was 104.6 and 100.8 respectively. For an
intervention targeting reduction of systolic blood pressure, 158 patients from PCC,
251 from SRC, 4 from HAVEN and 183 from YIMA met criteria for hypertension
treatment based on age and systolic blood pressure. The effects of interventions
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targets ranging from a decrease of 0 mmHg to 80 mmHg for each cohort is shown in
Figure 6.

Figure 6. Variances in sensitivity to systolic blood pressure decreases for the
four clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD
events are displayed in expected ASCVD events per 1,000 patients in the next 10
years.
For an intervention on total cholesterol, 557 patients from PCC, 822 from
SRC, 9 from HAVEN and 901 from YIMA meet criteria for treatment based on a
baseline ASCVD risk score greater than 7.5%. The effects of interventions targets
ranging from a decrease of 0 mg/dL to 150 mg/dL for each cohort is shown in Figure
7.
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Figure 7. Variances in sensitivity to total cholesterol decreases for the four
clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD
events are displayed in expected ASCVD events per 1,000 patients in the next 10
years.
An increase in HDL cholesterol was applied broadly to all patients in all clinic
cohorts. The effects of intervention targets ranging from an increase of 0 mg/dL to
100 mg/dL in HDL cholesterol for each cohort is shown in Figure 8.
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Figure 8. Variances in sensitivity to HDL cholesterol increases for the four
clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD
events are displayed in expected ASCVD events per 1,000 patients in the next 10
years.
Among the four cohorts the smoking prevalence was 14.1%, 30.9%, 7.3%,
and 9.1% for the PCC, SRC, HAVEN and YIMA clinic cohorts respectively. The
effects of smoking cessation interventions with probabilities ranging from 0 to 1.0 for
each cohort is shown in Figure 9.
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Figure 9. Variances in sensitivity to smoking cessation interventions for the
four clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD
events are displayed in expected ASCVD events per 1,000 patients in the next 10
years.

Application: Secondary Analysis of Clinic Cohorts
A secondary analysis of the clinic cohorts was performed to determine if using
the last known blood pressure instead of the one-year average significantly changed
any of the results. The baseline normalized aggregate risk for all clinic cohorts were
within 1 ASCVD event of the previously calculated baseline using the average
systolic blood pressure. The rest of the analysis remained mostly unchanged except
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for a slightly different sensitivity curve to systolic blood pressure interventions,
shown in Figure 10.

Figure 10. Variances in sensitivity to systolic blood pressure decreases for
the four clinic cohorts using the last known systolic blood pressure instead of the
average. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN (Brown),
and YIMA (Black). Decreases in normalized aggregate risk of ASCVD events are
displayed in expected ASCVD events per 1,000 patients in the next 10 years.

Application: Effect of Quality Improvement Interventions on the Clinic
Cohorts
A total of 38 different Cochrane Review articles describing lifestyle
interventions for direct or indirect ASCVD prevention were found. Twelve described
diet and exercise interventions, eight described interventions on blood pressure
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alone, fourteen described different methods of smoking cessation, and one
described effects of statin therapy.
Of the twelve diet and exercise interventions, seven had statistically
significant effects on at least one of the modifiable risk factors. These seven
interventions are described below.
•

Usinger et al. (2012) described the use of fermented milk to lower
systolic blood pressure on a general population by 2.45 mmHg. This
effect was applied to all patients in all clinic cohorts who had a baseline
systolic blood pressure above 110 mmHg.8

•

Rees et al. (2013) described the use of general dietary advice given by
providers. As compared to no advice, this intervention was found to
have statistically significant effects on total cholesterol and systolic
blood pressure on a general population. For male patients, total
cholesterol decreased by 9.2 mg/dL, but no significant effect was found
for women. For patients with a high risk of cardiovascular disease, the
decrease in systolic blood pressure was 2.95 mmHg, but there was no
statistically significant effect for the general population. High risk was
not well defined in Rees et al. and therefore a cutoff of 7.5% per
individual patient was used for the purpose of our analysis. A lower
bound of 80 mg/dL for total cholesterol and 110 mmHg was used for
systolic blood pressure interventions.9

•

Hartley et al. (2013) reviewed the effects of interventions to increase
fruit and vegetable consumption. Although studies which provided
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fruits and vegetables were included in the review, they were found to
have no benefit across all variables compared to interventions which
focused on advice only. Among a general population, advice to
increase fruit and vegetable consumption was found to have a 3.0
mmHg decrease in systolic blood pressure. We used the lower bound
of 110 mmHg for this intervention.10
•

Rees et al. (2013) reviewed the effects of a Mediterranean diet on
many risk factors. It was found that among a general population
adhering to a Mediterranean diet, total cholesterol was decreased by
6.2 mg/dL. A lower bound of 80 mg/dL was utilized when applying this
intervention to the clinic cohorts.11

•

Ebrahim et al. (2011) compiled the results of multifactorial
interventions for the primary prevention of ASCVD. These interventions
consisted of counseling and education. They found that these
interventions had no benefit for a general population but had significant
beneficial effects for patients with hypertension or diabetes mellitus.
Therefore, this intervention was only applied to those patients with
either hypertension or diabetes within our clinic cohorts. Total
cholesterol was reduced by 2.7 mg/dL, while systolic blood pressure
was decreased by 2.74 mmHg for those not on antihypertensive drugs
while it was decreased by 3.89 mmHg for patients on antihypertensive
drugs. Smoking cessation counseling and education resulted in a 15%
reduction in smoking prevalence.12
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•

Adler et al. (2013) studied the effects of a reduced salt diet on the
general population. The advice to decrease dietary salt had a 4.14
mmHg decrease in systolic blood pressure among patients with
hypertension but no effect on normotensive patients.13

•

Siebenhofer et al. (2011) covered the effects of dietary interventions
aimed at weight reduction on ASCVD prevention. The only significant
effect was on systolic blood pressure with an average decrease of 4.49
mmHg among hypertensive patients. A lower bound of 110 mmHg was
again used on the intervention.14

Of the eight Cochrane Reviews found to target hypertension as a primary
prevention strategy for ASCVD, only three were included in this study. Reasons for
exclusion were that they were either based on pharmacotherapies, which is out of
the scope of this study, or did not include outcomes on systolic blood pressure.
Since these interventions were focused on hypertension, the effects were applied
only to patients who had a systolic blood pressure above 140 mmHg if they were
under 60 years of age or 150 mmHg for 60 or more years of age, or patients who
were already in treatment for hypertension. These interventions are described
below.
•

Glynn et al. (2010) reviewed the effects of multiple types of
interventions including self-monitoring, health professional led care,
organizational interventions, and appointment reminders, respectively.
Organizational interventions were further described as interventions
that aimed to improve the delivery of care. One example includes the
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Hypertension Detection and Follow-Up Program from 1979.15 These
interventions reduced systolic blood pressure by 2.53 mmHg, 2.52
mmHg, 6.00 mmHg and 4.56 mmHg, respectively. Patient and
physician education were also studied independently but neither was
found to have a significant effect on systolic blood pressure.16
•

Dickinson et al. (2006) described the used of calcium supplements for
the treatment of hypertension. For hypertensive patients with a
baseline

systolic

blood

pressure

above

145

mmHg,

calcium

supplements were shown to decrease systolic blood pressure by 2.49
mmHg.17
•

Dickinson et al. (2008) compiled the effects of relaxation techniques
on hypertensive patients. These techniques were found to have a 5.5
mmHg decrease in systolic blood pressure.18

The fourteen Cochrane Reviews found describing smoking cessation
interventions all reported the odds ratio as its final outcome. The odds ratio was not
possible to use in this model as we would need to know the smoking cessation rate
without an intervention. Therefore, smoking cessation interventions were omitted
from this part of the study. Similarly, the one intervention found specifically for
lowering of total cholesterol was pharmacologic in nature and out of the scope of this
study. The overall results for each of the interventions described above are shown in
Table 6.
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Table 5. Summary of interventions chosen for application from Cochrane
reviews. Some of the interventions described have different effects on different
populations.
Changes to Risk Factors
Interventions

Target patient
population

Diet Advice from Rees et
al., 2013 (Chol and BP)

Male patients /
Patients with an
ASCVD risk > 7.5%

Fermented Milk from
Usinger et al., 2012 (BP)

All patients

-2.45

Advice to eat F&V from
Hartley et al., 2013 (BP)

All patients

-3.00

Mediterranean Diet from
Rees et al., 2013 (Chol)

All patients

Multifactor Intervention
from Ebrahim et al., 2011
(Chol, BP, Smoke)

Hypertension or
diabetes mellitus
diagnosis
(Antihypertensives /
No treatment)

Low Salt Diet from Adler
et al., 2013 (BP)

Patients with
hypertension

-4.14

Patients with
hypertension

-4.49

Patients with
hypertension

-2.53

Patients with
hypertension

-2.52

Patients with
hypertension

-6.00

Patients with
hypertension

-4.56

Patients with
hypertension

-2.49

Patients with
hypertension

-5.50

Weight Reduction Diet
from Siebenhofer et al.,
2011 (BP)
Self Monitoring of HTN
from Glynn et al., 2010
(BP)
Health Professional Led
Care of HTN from Glynn
et al., 2010 (BP)
Organizational
Interventions on HTN
from Glynn et al., 2010
(BP)
Appointment Reminders
on HTN from Glynn et al.,
2010 (BP)
Calcium Supplements for
HTN from Dickinson et
al., 2009 (BP)
Relaxations for HTN from
Dickinson et al., 2009 (BP)

Total
Cholesterol
(mg/dL)
-9.2 / 0

HDL
Cholesterol
(mg/dL)

Systolic
BP
(mmHg)

Smoking
Cessation

0 / -2.95

-6.20

-2.7/-2.7

-3.89 /
-2.74

15% / 15%
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Table 6. Estimated changes in normalized aggregate risk of various
interventions. Each of the interventions listed has an effect on systolic blood
pressure, total cholesterol, HDL cholesterol or smoking status. Data on the effect
size was pulled from Cochrane Reviews. The baseline risk and the changes are
shown in expected ASCVD events per 1,000 patients in the next 10 years. Dark
green shading indicates the interventions with the greatest positive outcome for each
clinic cohort. The HAVEN clinic with its lower baseline risk appears to respond more
efficiently to interventions aimed at the general population compared to the other
three clinics.
Interventions

Change in Normalized Aggregate Score
PCC
SRC
HAVEN
YIMA

Baseline risk (events per 1,000
patients)

104.60

117.33

55.21

100.80

Diet Advice from Rees et al., 2013
(Chol and BP)

-4.71

-4.72

-2.02

-3.77

Fermented Milk from Usinger et al.,
2012 (BP)

-3.25

-3.42

-1.32

-2.53

Advice to eat F&V from Hartley et al.,
2013 (BP)

-3.97

-4.19

-1.61

-3.10

-2.30

-2.26

-1.20

-1.62

-4.63

-5.39

-0.86

-2.06

-2.20

-2.45

-0.79

-1.52

-4.53

-4.84

-0.60

-2.88

Self-Monitoring of HTN from Glynn et
al., 2010 (BP)

-2.57

-2.74

-0.34

-1.63

Health Professional Led Care of HTN
from Glynn et al., 2010 (BP)

-2.56

-2.73

-0.34

-1.63

Organizational Interventions on HTN
from Glynn et al., 2010 (BP)

-6.00

-6.44

-0.79

-3.84

Appointment Reminders on HTN from
Glynn et al., 2010 (BP)

-4.60

-4.91

-0.61

-2.93

Calcium Supplements for HTN from
Dickinson et al., 2009 (BP)

-0.99

-1.51

-0.21

-0.66

Relaxations for HTN from Dickinson et
al., 2008 (BP)

-5.52

-5.91

-0.73

-3.53

Mediterranean Diet from Rees et al.,
2013 (Chol)
Multifactor Intervention from
Ebrahim et al., 2011 (Chol, BP,
Smoke)
Low Salt Diet from Adler et al., 2013
(BP)
Weight Reduction Diet from
Siebenhofer et al., 2011 (BP)
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Discussion
The results from our simulations with randomly generated cohorts with
indistinguishable demographics demonstrated that there is a large amount of
potential variance in baseline normalized aggregate risk of ASCVD and response to
interventions. As a proof of concept these results support the utility of the tool we
have created to analyze clinic populations. These results were replicable when
applied to four real clinic cohorts. The ASCVD risk reduction from a given
intervention was dependent on baseline normalized aggregate risk and average
value of the modified risk factor. Furthermore, the effects of lifestyle interventions on
ASCVD risk could be modeled through their effects on the modifiable risk factors by
our tool. The intervention with the highest ASCVD risk reduction was not the same
across all cohorts.
The 10,000 randomly generated cohorts with the same demographic
characteristics had significantly different baseline normalized aggregate risk.
Importantly, this demonstrates that population averages should not be used in the
10-year ASCVD risk calculator to estimate the risk of a population. Doing so would
result in inaccurate prediction of normalized aggregate risk. Further, when we tested
the response of these randomly generated cohorts to single variable interventions,
the response curves indicated that there is decreasing marginal risk reduction to
interventions aiming to reduce total cholesterol, HDL cholesterol, and systolic blood
pressure. These patterns were also observed on the four real clinic populations with
the addition of the fact that response to the same interventions differed by baseline
risk. In the case of total cholesterol and systolic blood pressure, we observed that
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cohorts responded differently to interventions on the same risk factor but that these
relationships may change depending on the effect size of said intervention. In other
words, the effect of interventions on systolic blood pressure will not always be better
for cohort A compared to cohort B but that this relationship depends on the amount
of change in systolic blood pressure.
Chu et al. (2016) demonstrated that the use of simulation with the 10-year
ASCVD risk calculator has a role in choosing high-yield primary prevention
interventions.2 They created hypothetical patients of different characteristics and
estimated the effect of different interventions on each of these patients. That study
created a chart that would allow a provider to prioritize an intervention for any given
patient based on the expected ASCVD risk decrease. However, their models are
limited to individual patients and not whole populations. Our results suggest that
similar methods are applicable to whole populations. Franco et al. (2007) used
similar statistical techniques to our model using the Framingham Risk Score.3 They
concluded that smoking-cessation was the most cost-effective intervention for the
primary prevention of ASCVD within the Framingham cohorts. With our tool, we
aimed to combine the principles of these two papers to guide clinics in choosing the
best primary prevention intervention(s) for their specific patient population.
The

effect

of

thirteen

different

non-pharmacologic

evidence-based

interventions on systolic blood pressure, total cholesterol, HDL cholesterol and/or
smoking prevalence had different effects on ASCVD risk across four clinic cohorts.
According to our model, the highest yield intervention for the HAVEN clinic was to
implement a diet advice program as described in Rees at al., while all the other
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clinics would benefit most from an organizational quality improvement project to
address hypertension as described in Glynn et al.9,16 However, the organizational
interventions described in Glynn et al. varied in type and effect size making the
effects less reproducible. The only shared commonality is that they “aimed to
improve the delivery of care.” Another high yield intervention among three of the
cohorts was a weight reducing diet as described by Siebenhofer et al. (2011)14 It is
worth noting that this intervention was not limited to advice only and may require a
great amount of resources to fully implement. Therefore, any clinic using the tool to
choose an intervention could face a choice between these two difficult to implement
options. However, they approach this decision with more knowledge of the expected
outcomes. Alternatively, other interventions could be relatively easy to implement
and have a great impact, such as diet advice as described by Rees et al.9
The HAVEN clinic had the most significantly different population among the
four clinics. The patients were younger, there were far more patients who identified
as Hispanic and the baseline normalized aggregate ASCVD risk was significantly
lower. As such it was not surprising that its responses to the many nonpharmacologic interventions were also different from the other three clinics. At the
HAVEN clinic, interventions that target the general population were much more
successful than interventions that target high risk populations (i.e. patients with
hypertension). This is in contrast to the three other clinics where the opposite was
true.
Another factor clinics may consider is the number of patients involved in each
intervention. The fruits and vegetable dietary interventions were applied to entire
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clinic cohorts whereas the hypertension interventions described by Glynn et al. were
only applied to hypertensive patients. So providers will have a tradeoff between high
yield interventions on a few high risk patients or more broad interventions with
similar results on the overall ASCVD risk.
The tool we have created allows the ACC/AHA 10-year ASCVD risk calculator
to be used as a metric to monitor and reduce ASCVD risk in a clinic cohort. Clinic
providers and/or administrators will be able to use the tool to allocate their limited
resources to the ASCVD prevention strategy with the highest predicted impact
based on quantitative predictions. Ultimately we envision such a tool being used by
clinics to select and monitor primary preventions strategies for ASCVD, similarly to
how a physician already uses the tool to guide preventions strategies at the
individual patient level. For example, a clinic hires a new health educator and they
are faced with choosing a new project for this employee: smoking cessation, or
hypertensive management education. While it would be simple choice if everyone in
the clinic cohort is a smoker but there are no patients with hypertension (or vice
versa), the choice becomes more complicated if that is not the case. The current
literature does not offer a threshold prevalence above which a smoking cessation
intervention becomes more efficient at reducing AVCD risk than hypertension
education; we discovered that the change in risk varies significantly by cohort. The
tool we have created would be able to tell the health educator which of these
interventions would have the greatest impact on the population of this clinic. After
initiation of the intervention, the tool can also be used to continuously monitor the
ASCVD risk in the community for continuing quality improvements cycles.
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At a larger scale, hospitals are now mandated to conduct community health
assessments and identify areas of need.19 By incorporating data from the EHR and
community health assessments, the tool we created can model the effects of
interventions on whole communities. This data can be utilized by hospitals or public
health departments to supplement community needs assessments and guide
policy/programs.19 Community leaders would, for example, be able to prioritize their
resources to an exercise campaign or a farmers’ market, depending on the effect
sizes estimated by our tool. The reports generated by our tool may even be used as
supporting evidence in grant application or project proposals. The 2003 AHA Guide
for Improving Cardiovascular Health at the Community Level suggests that
community based interventions be chosen based solely on the identification of high
risk groups and/or the feasibility of said interventions (i.e. the prevalence of smoking,
and the feasibility of an ad campaign).20 In this guideline, efficacy of interventions at
the community level is not accounted for, however our tool can supplement this
decision-making process by providing quantitative efficacy predictions.

Limitations of This Study
This study has important limitations. Our study relies on assumptions made
for our statistical prediction method. The first assumption is that all factors except the
one being modified remain unchanged during the interventions. For example, we
assume that while patients participate in an intervention on blood pressure that their
age, smoking status, diabetes diagnosis and cholesterol levels remain unchanged.
Another assumption in our study is that effects described in Cochrane reviews
will be the same among the patient populations in our study. There are likely factors
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beyond our model that will affect the results and therefore the observed ASCVD risk
reduction observed will also differ.
Another set of assumptions are the lower boundaries of 110 mmHg and 80
mg/dL used for systolic blood pressure and total cholesterol, respectively. Here we
assumed that patients who started above these lower boundaries would not be able
to go below it. This was meant to simulate the way real patients may respond to
interventions and the natural limits of any intervention. Though the boundaries were
chosen based on clinical experience, the real response by patients may vary.
Our included sample may have been biased. The patients with missing data
across all clinics had at least one statistically significant difference in their
demographics, suggesting systematic differences between these populations. For
example, patients with missing data tended to be younger in all clinics, likely
because they did not receive cholesterol screening or did not return to clinic. Among
three of the four clinics, patients with missing data were less likely to have a
diagnosis of diabetes mellitus. This likely reflects either not enough follow up to
establish the diagnosis or a closer follow up of patients who do have the diagnosis.
These differences indicate that patients excluded from analyses may have different
baseline risk and therefore may respond differently to the interventions. This also
brings up the fact that patient cohorts are not static and that new patients will join the
panel while other patients leave. These factors are not accounted for in our
estimates.
Lastly, we do not account for any of the other positive or negative effects of
any intervention outside of the ASCVD risk factors or on overall ASCVD risk. In the
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case of total cholesterol reduction for example, it has been shown that using statin
therapy has an effect on ASCVD risk beyond what is accounted for by total
cholesterol reduction.21

Next Steps
Ultimately, we aim to provide clinicians with the tools necessary to choose the
most efficient ASCVD prevention strategy. Though this application is currently only
able to identify the goals of therapy and expected impact of evidence-based
interventions, in the future it can be adapted to make recommendations using cost
efficiency data and/or cost estimates from the literature. For example, Pandya et al.
(2015) built a model that estimated cost-effectiveness for different statin therapy
thresholds using known data on their efficiency, their cost and the ASCVD 10-year
risk calculator.5 We envision statistical models similar to those used in Pandya et al.
2015 except applied at the clinic population level, using real-time data and across all
modifiable risk factors.5
Furthermore, the feasibility and adoption of such a tool remains to be
elucidated. We plan to perform a qualitative study to assess primary care clinic
directors’ ease of use, interpretation and applicability of the application. We then aim
to conduct a controlled trial involving several clinics randomized to use the tool or to
use usual quality improvement strategies to decrease ASCVD events. The objective
of such a trial would be to determine if the strategies and goals suggested by the
tool can outperform standard practices.
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